
|Videos|August 26, 2021
Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML
Expert continues discussion of IDH1 and IDH2 inhibitors in AML and examines prioritization of IDH1 and IDH2 inhibitors versus venetoclax in newly diagnosed AML.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Extended-Interval Tarlatamab Dosing Offers Pharmacists More Flexible Administration Windows in SCLC
2
Pharmacists Weigh Health, Not Just Weight, in Obesity Care
3
Cancer Among 9/11 Survivors Is Accelerating 25 Years Later
4
Pharmacists as the Glue in Cardio-Kidney-Metabolic Care
5




































































































